AbbVie Celebrates Official Launch - - BioPharm International

ADVERTISEMENT

AbbVie Celebrates Official Launch



AbbVie, a research-focused, specialty biopharmaceutical company that was spun off from Abbott, was officially launched on Jan. 2, 2013.  The new company will employ approximately 21,000 people in more than 40 countries, according to AbbVie’s news release.

The new company’s portfolio includes both growth brands and durable performers, including HUMIRA (adalimumab), AndroGel (testosterone gel), Lupron (leuprolide), Synagis (palivizumab, manufactured by MedImmune), Creon (pancrelipase), Synthroid (levothyroxine sodium), Kaletra (lopinavir/ritonavir), Norvir (ritonavir), and Zemplar (paricalcitol). In addition, AbbVie’s pipeline contains compounds in more than 20 mid- to late-stage clinical programs as well as discovery efforts in diseases including Hepatitis C, rheumatoid arthritis, psoriasis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, spondyloarthropathies, multiple myeloma, and endometriosis.

"Our commitment at AbbVie is to build on Abbott's 125-year heritage and address some of the world's most serious health issues," said Richard A. Gonzalez, AbbVie’s chairman of the board and chief executive officer, in the press release. "We intend AbbVie's enduring legacy to be one of finding treatments for patients with serious health care needs."

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Lundbeck CEO Resigns Due to Code of Conduct Breach
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Janssen Partners with Transposagen Biopharmaceuticals for CAR-T Therapies
November 24, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Author Guidelines

Click here